254 related articles for article (PubMed ID: 32882250)
1. Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use.
Wieruszewski PM; Wittwer ED; Kashani KB; Brown DR; Butler SO; Clark AM; Cooper CJ; Davison DL; Gajic O; Gunnerson KJ; Tendler R; Mara KC; Barreto EF
Chest; 2021 Feb; 159(2):596-605. PubMed ID: 32882250
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II for the Treatment of Vasodilatory Shock.
Khanna A; English SW; Wang XS; Ham K; Tumlin J; Szerlip H; Busse LW; Altaweel L; Albertson TE; Mackey C; McCurdy MT; Boldt DW; Chock S; Young PJ; Krell K; Wunderink RG; Ostermann M; Murugan R; Gong MN; Panwar R; Hästbacka J; Favory R; Venkatesh B; Thompson BT; Bellomo R; Jensen J; Kroll S; Chawla LS; Tidmarsh GF; Deane AM;
N Engl J Med; 2017 Aug; 377(5):419-430. PubMed ID: 28528561
[TBL] [Abstract][Full Text] [Related]
3. Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.
Rodriguez R; Cucci M; Kane S; Fernandez E; Benken S
J Intensive Care Med; 2020 Apr; 35(4):327-337. PubMed ID: 30563433
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Observational Cohort Study of Angiotensin II in Shock.
Smith SE; Newsome AS; Guo Y; Hecht J; McCurdy MT; Mazzeffi MA; Chow JH; Kethireddy S
J Intensive Care Med; 2022 Jan; 37(1):75-82. PubMed ID: 33231111
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support.
Wieruszewski PM; Seelhammer TG; Barreto EF; Busse LW; Chow JH; Davison DL; Gaglani B; Khanna AK; Ten Lohuis CC; Mara KC; Wittwer ED
J Intensive Care Med; 2023 May; 38(5):464-471. PubMed ID: 36524274
[No Abstract] [Full Text] [Related]
6. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.
Wieruszewski PM; Bellomo R; Busse LW; Ham KR; Zarbock A; Khanna AK; Deane AM; Ostermann M; Wunderink RG; Boldt DW; Kroll S; Greenfeld CR; Hodges T; Chow JH;
Crit Care; 2023 May; 27(1):175. PubMed ID: 37147690
[TBL] [Abstract][Full Text] [Related]
7. Vasopressor therapy in critically ill patients with shock.
Russell JA
Intensive Care Med; 2019 Nov; 45(11):1503-1517. PubMed ID: 31646370
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II Administration in Patients With COVID-19 Shock.
Ofosu-Barko K; Liu Y; Alkhatib Tamimi F; Al Husami W; Ganatra S; Resnic F; Shah SP
Crit Pathw Cardiol; 2021 Jun; 20(2):100-102. PubMed ID: 33031192
[TBL] [Abstract][Full Text] [Related]
9. Management of Refractory Vasodilatory Shock.
Jentzer JC; Vallabhajosyula S; Khanna AK; Chawla LS; Busse LW; Kashani KB
Chest; 2018 Aug; 154(2):416-426. PubMed ID: 29329694
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II in Vasodilatory Shock.
Wakefield BJ; Busse LW; Khanna AK
Crit Care Clin; 2019 Apr; 35(2):229-245. PubMed ID: 30784606
[TBL] [Abstract][Full Text] [Related]
11. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent.
Argenziano M; Chen JM; Choudhri AF; Cullinane S; Garfein E; Weinberg AD; Smith CR; Rose EA; Landry DW; Oz MC
J Thorac Cardiovasc Surg; 1998 Dec; 116(6):973-80. PubMed ID: 9832689
[TBL] [Abstract][Full Text] [Related]
12. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock.
Albertson TE; Chenoweth JA; Lewis JC; Pugashetti JV; Sandrock CE; Morrissey BM
Expert Rev Clin Pharmacol; 2022 Aug; 15(8):959-976. PubMed ID: 35920615
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic Agents for the Treatment of Vasodilatory Shock.
Knotzer H; Poidinger B; Kleinsasser A
Curr Pharm Des; 2019; 25(19):2133-2139. PubMed ID: 31272348
[TBL] [Abstract][Full Text] [Related]
14. Lack of an effect of body mass on the hemodynamic response to arginine vasopressin during septic shock.
Lam SW; Bauer SR; Cha SS; Oyen LJ
Pharmacotherapy; 2008 May; 28(5):591-9. PubMed ID: 18447658
[TBL] [Abstract][Full Text] [Related]
15. [Arginine vasopressin in vasodilatory shock: a new therapy approach?].
Dünser M; Wenzel V; Mayr AJ; Hasibeder WR
Anaesthesist; 2002 Aug; 51(8):650-9; discussion 659-60. PubMed ID: 12391525
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial.
Bokoch MP; Tran AT; Brinson EL; Marcus SG; Reddy M; Sun E; Roll GR; Pardo M; Fields S; Adelmann D; Kothari RP; Legrand M
BMJ Open; 2023 Nov; 13(11):e078713. PubMed ID: 37984940
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II in Refractory Septic Shock.
Antonucci E; Gleeson PJ; Annoni F; Agosta S; Orlando S; Taccone FS; Velissaris D; Scolletta S
Shock; 2017 May; 47(5):560-566. PubMed ID: 27879559
[TBL] [Abstract][Full Text] [Related]
18. Intravenous arginine vasopressin infusion in refractory vasodilatory shock: a clinical study.
Agrawal A; Singh VK; Varma A; Sharma R
Indian J Pediatr; 2012 Apr; 79(4):488-93. PubMed ID: 21922300
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management.
Senatore F; Balakumar P; Jagadeesh G
Pharmacol Res; 2021 Dec; 174():105916. PubMed ID: 34597810
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
Senatore F; Jagadeesh G; Rose M; Pillai VC; Hariharan S; Liu Q; McDowell TY; Sapru MK; Southworth MR; Stockbridge N
Am J Cardiovasc Drugs; 2019 Feb; 19(1):11-20. PubMed ID: 30144016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
